ACOG (Alpha Cognition) Current Accrued Expense: $3.88 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACOG Alpha Cognition Inc ACOG
32 GF Score
Price $8.58
! 3 Warning Signs
View Full Analysis

What is Alpha Cognition Current Accrued Expense?

Alpha Cognition ACOG +7.38% 32 Current Accrued Expense is $3.88 Mil as of Mar. 2026. GuruFocus rates ACOG with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Alpha Cognition's Current Accrued Expense for the quarter that ended in Mar. 2026 was $3.88 Mil.

Alpha Cognition's quarterly Current Accrued Expense increased from Sep. 2025 ($5.69 Mil) to Dec. 2025 ($5.91 Mil) but then declined from Dec. 2025 ($5.91 Mil) to Mar. 2026 ($3.88 Mil).

Alpha Cognition's annual Current Accrued Expense increased from Dec. 2023 ($0.92 Mil) to Dec. 2024 ($1.57 Mil) and increased from Dec. 2024 ($1.57 Mil) to Dec. 2025 ($5.91 Mil).

Alpha Cognition Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Alpha Cognition's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alpha Cognition Current Accrued Expense Chart

Alpha Cognition Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 0.27 0.28 0.92 1.57 5.91

Alpha Cognition Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.75 2.06 5.69 5.91 3.88
ACOG
32GF Score
Alpha Cognition Inc ACOG
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alpha Cognition Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $3.88 Mil mean?
Alpha Cognition (ACOG) has a Current Accrued Expense of $3.88 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Alpha Cognition and its competitors.
Is Alpha Cognition's Current Accrued Expense too high?
Alpha Cognition's current Current Accrued Expense is $3.88 Mil. Overall, Alpha Cognition has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Cognition's Current Accrued Expense compare to MENS and NGEN?
Alpha Cognition's Current Accrued Expense of $3.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Alpha Cognition and its competitors. Alpha Cognition's current Current Accrued Expense is $3.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Cognition stock overvalued right now?
Alpha Cognition (ACOG) has a current Current Accrued Expense of $3.88 Mil. The current Current Accrued Expense is $3.88 Mil. Alpha Cognition's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Alpha Cognition (ACOG), the current Current Accrued Expense is $3.88 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alpha Cognition Business Description

Other Exchanges 7N70:Germany
Address 1200 - 750 West Pender Street, Vancouver, BC, CAN, V6C 2T8
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
32GF Score

Get the complete analysis for ACOG

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.58
Price